| DESCRIPTION | - A.M. JUBB et al., J. Pathol., (20010000), vol. 195, pages 111 - 134 | - |
| DESCRIPTION | - A.M. JUBB et al., J. Pathology, (20010000), vol. 195, pages 111 - 34 | - |
| DESCRIPTION | - ANSELL; S.M. et al., Mayo Clin. Proc., (20050000), vol. 80, no. 8, pages 1087 - 97 | - |
| DESCRIPTION | - APARICIO et al., Curr. Opin. Invest. Drugs, (20020000), vol. 3, no. 4, pages 627 - 33 | - |
| DESCRIPTION | - BELINSKY, S.A., Nature Rev. Cancer, (20040000), vol. 4, pages 1 - 11 | - |
| DESCRIPTION | - BENNETT J. M., et al., Ann. Intern. Med., (19850000), vol. 103, no. 4, pages 620 - 5 | - |
| DESCRIPTION | - BESA E. C., Med. Clin. North Am., (19920000), vol. 76, no. 3, pages 599 - 617 | - |
| DESCRIPTION | - BROWN et al., Biochemical Preparations, (19550000), vol. 4, pages 70 - 76 | - |
| DESCRIPTION | - CAS, no. 320-67-2 | - |
| DESCRIPTION | - EMENS, L.A. et al., Curr. Opinion Mol. Ther., (20010000), vol. 3, no. 1, pages 77 - 84 | - |
| DESCRIPTION | - FOSTER et al., Adv. Drug Res., (19850000), vol. 14, pages 1 - 36 | - |
| DESCRIPTION | - FROMMER, M. et al., Proc. Nat'l Acad. Sci. USA, (19920000), vol. 89, pages 1827 - 31 | - |
| DESCRIPTION | - GATELY, J. Nucl. Med., (19860000), vol. 27, page 388 | - |
| DESCRIPTION | - G. GARCIA-MANEROM. L. STOLTZM. R. WARDH. KANTARJIANS. SHARMA, Leukemia, (20080000), vol. 22, pages 1680 - 84 | - |
| DESCRIPTION | - G. GIFFORD et al., Clin. Cancer Res., (20040000), vol. 10, pages 4420 - 26 | - |
| DESCRIPTION | - GORDON, Drug Metab. Dispos., (19870000), vol. 15, page 589 | - |
| DESCRIPTION | - GRUNDMANN et al., Chem. Ber., (19540000), vol. 87, pages 19 - 24 | - |
| DESCRIPTION | - JEMAL et al., CA Cancer J. Clin., (20050000), vol. 55, no. 1, pages 10 - 30 | - |
| DESCRIPTION | - J.G. HERMANS.B. BAYLIN, N. Engl. J. Med., (20030000), vol. 349, pages 2042 - 54 | - |
| DESCRIPTION | - K. APPLETON et al., J. Clin. Oncol., (20070000), vol. 25, no. 29, pages 4603 - 4609 | - |
| DESCRIPTION | - KUSHNER et al., Can. J. Physiol. Pharmacol., (19990000), vol. 77, pages 79 - 88 | - |
| DESCRIPTION | - LAIRD, P.W., Nature Rev. Cancer, (20030000), vol. 3, pages 253 - 66 | - |
| DESCRIPTION | - LI et al., Bioinformatics, (20020000), vol. 18, pages 1427 - 31 | - |
| DESCRIPTION | - LIJINSKY, Food Cosmet. Toxicol., (19820000), vol. 20, page 393 | - |
| DESCRIPTION | - LIJINSKY, J. Nat. Cancer Inst., (19820000), vol. 69, page 1127 | - |
| DESCRIPTION | - LIST et al., J. Clin. Oncol., (19900000), vol. 8, page 1424 | - |
| DESCRIPTION | - MANGOLD, Mutation Res, (19940000), vol. 308, page 33 | - |
| DESCRIPTION | - M.V. BROCK et al., N. Engl. J. Med., (20080000), vol. 358, no. 11, pages 1118 - 28 | - |
| DESCRIPTION | - P.A. JONESS.B. BAYLIN, Nature Rev. Gen., (20020000), vol. 3, pages 415 - 28 | - |
| DESCRIPTION | - PENICHET, M.L.MORRISON, S.L., J. Immunol. Methods, (20010000), vol. 248, pages 91 - 101 | - |
| DESCRIPTION | - P. FENAUX et al., Lancet Oncol., (20090000), vol. 10, no. 3, pages 223 - 32 | - |
| DESCRIPTION | - PISKALA, Collect. Czech. Chem. Comm., (19670000), vol. 32, pages 3966 - 3976 | - |
| DESCRIPTION | - PISKALA et al., Synthetic Procedures in Nucleic Acid Chemistry, Wiley Interscience, (19680000), vol. 1, pages 107 - 108 | - |
| DESCRIPTION | - P.M. DAS et al., Mol. Cancer, (20060000), vol. 5, no. 28 | - |
| DESCRIPTION | - RAO, K.V., American Journal of Health-System Pharmacy, (20070000), vol. 64, no. 17, pages 1799 - 1807 | - |
| DESCRIPTION | - SILVERMAN et al., Blood, (20050000), vol. 106, no. 11 | - |
| DESCRIPTION | - SILVERMAN et al., J. Clin. Oncol., (20020000), vol. 20, no. 10, pages 2429 - 2440 | - |
| DESCRIPTION | - S. NAND et al., Leukemia and Lymphoma, (20080000), vol. 49, no. 11, pages 2141 - 47 | - |
| DESCRIPTION | - WADE, D., Chem. Biol. Interact., (19990000), vol. 117, page 191 | - |
| DESCRIPTION | - ZELLO, Metabolism, (19940000), vol. 43, page 487 | - |
| DESCRIPTION | - ZENT, C.S. et al., Current Oncology Reports, (20070000), vol. 9, pages 345 - 52 | - |
| OPPOSITION | - "5-Azacytidine", Kenneth A. Connors, Gordon L. Amidon, Valentino J. Stella, Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, Second Edition, John Wiley & Sons, Inc., (19860101), page 2pp, 239, XP055735934 | - |
| OPPOSITION | - Anonymous, "Azacitidine (passage)", IARC monographs on the evaluation of carcinogenic risks to humans, (19900101), vol. 50 - Pharmaceutical Drugs, pages 47 - 48, XP055735927 | - |
| OPPOSITION | - Anonymous, "Bristol Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001", (20191210), URL: https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Presents-Overall-Survival-and-Safety-Data-From-Pivotal-CC-486-Study-QUAZAR-AML-001/default.aspx, XP093132006 | - |
| OPPOSITION | - Anonymous, "Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001", Bristol Myers Squibb, (20191210), page 3pp, Bristol Myers Squibb, URL: https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Presents-Overall-Survival-and-Safety-Data-From-Pivotal-CC-486-Study-QUAZAR-AML-001/default.aspx, (20201001), XP055735907 | - |
| OPPOSITION | - Anonymous, "Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia", (20210618), URL: https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Onureg-azacitidine-tablets-as-Frontline-Oral-Maintenance-Therapy-for-Adults-with-Acute-Myeloid-Leukemia/default.aspx, XP093132008 | - |
| OPPOSITION | - Anonymous, "European Medicines Agency ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE FOR GUIDANCE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES", (20060101), pages 1 - 32, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002823.pdf, (20150904), XP055211303 | - |
| OPPOSITION | - Anonymous, "European Medicines Agency ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE FOR GUIDANCE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES", (20060101), pages 19 - 20, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002823.pdf, XP055211303 | - |
| OPPOSITION | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA", (20080801), page 1, XP055735918 | - |
| OPPOSITION | - Anonymous, "IARC monographs on the evaluation of carcinogenic risks to humans", Pharmaceutical Drugs, (19900101), vol. 50, pages 47 - 48, XP055735927 | - |
| OPPOSITION | - Anonymous, "PRESS RELEASE: Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes", Press release Pharmion Corporation, FierceBiotech, (20070829), pages 1 - 2, Press release Pharmion Corporation, URL: https://www.fiercebiotech.com/biotech/press-release-pharmion-s-oral-azacitidine-granted-fast-track-status-for-myelodysplastic, (20240205), XP093127431 | - |
| OPPOSITION | - Anonymous, "VIDAZA", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20080801), page 1, XP055735918 | - |
| OPPOSITION | - Aparicio Ana; Weber Jeffrey S, "Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, US , (20020401), vol. 3, no. 4, ISSN 1472-4472, pages 627 - 633, XP009110545 | - |
| OPPOSITION | - Aulton, "The design and Manufacture of Medicines", Aulton's Pharmaceutics, (20070000), pages 454 - 455, XP055735913 | - |
| OPPOSITION | - Beisler J A, Abbasi M M, Kelley J A, Driscoll J S, "Chemistry of antitumor triazine nucleosides. An improved synthesis of Dihydro-5-AZacytidine", JOURNAL OF CARBOHYDRATES. NUCLEOSIDES NUCLEOTIDES., MARCEL DEKKER, BASEL., CH, CH , (19770101), vol. 4, no. 5, ISSN 0094-0585, pages 281 - 299, XP009089416 | - |
| OPPOSITION | - "Chapter 10: Drug Delivery Systems", Pandit Nita K, Introduction to the pharmaceutical sciences, (20070101), pages 147 - 159, XP093044448 | - |
| OPPOSITION | - Cheung Yuen-Wah, B. Rao Vishnuvajjala, Nancy L. Morris, Karl P. Flora, "Stability of azacitidine in infusion fluids", American Journal of Hospital Pharmacy, (19840601), vol. 41, pages 1156 - 1159, XP093131360 | - |
| OPPOSITION | - Kenneth A. Connors, Gordon L. Amidon, Valentino J. Stella, "5-Azacytidine", Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, Second Edition, John Wiley & Sons, Inc., (19860101), page 2pp, 239, XP055735934 | - |
| OPPOSITION | - Lachman Leon, Lieberman Herbert A., Kanic Joseph L., The Theory and Practice of Industrial Pharmacy, 3rd ed., (19860101), pages 331 - 332, XP093132034 | - |
| OPPOSITION | - Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig, "The Theory and Practice of Industrial Pharmacy Third Edition /Passage/", VARGHESE PUBLISHING HOUSE , (19860101), page 1pp, 331, 332, XP055735916 | - |
| OPPOSITION | - Leon Shargel ; Susanna Wu-Pong ; Andrew B.C. Yu, "Chapter 17: Modified-Release Drug Products", Applied Biopharmaceutics & Pharmacokinetics Fifth Edition, McGraw-Hill, (20050101), page 515, ISBN 0-07-137550-3, XP055926624 | - |
| OPPOSITION | - LIN K.-T., ET AL, "High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine.", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (19811101), vol. 70, no. 11, ISSN 0022-3549, pages 1228 - 1232, XP002611849 | - |
| OPPOSITION | - Mark Gibson, Pharmaceutical Preformulation and Formulation - A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, (20090101), page 332, XP055879181 | - |
| OPPOSITION | - Michael E. Aulton, Aulton's Pharmaceutics: The Design and Manufacture of Medicines, Third Edition, (20070101), pages 5 - 6, 9, XP093131997 | - |
| OPPOSITION | - Michael E. Aulton, "dosage from design and manufacture ", Aulton's Pharmaceutics: The Design and Manufacture of Medicines, (20070101), pages 454 - 455, XP055924335 | - |
| OPPOSITION | - Michael E. Aulton, "PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition /Passage/", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 222 - 223, ISBN 0-443-05517-3, XP055735938 | - |
| OPPOSITION | - Mund C; Brueckner B; Lyko F, "Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications", Epigenetics : official journal of the DNA Methylation Society, Landes Bioscience, US, US , (20060301), vol. 1, no. 1, ISSN 1559-2308, pages 7 - 13, XP008109916 | - |
| OPPOSITION | - National Cancer Institute, National Institutes Of Health, "Bioassay of 5-azacytidine for possible carcinogenicity", Carcinogenesis, Technical Report Series No. 42, (19780101), pages 2pp, 3 - 4, XP055352926 | - |
| OPPOSITION | - National Cancer Institute, National Institutes Of Health, "Bioassay of 5-azacytidine for possible carcinogenicity", Carcinogenesis, Technical Report Series No. 42, (19780101), pages 2pp, iii - 4, XP055352926 | - |
| OPPOSITION | - Pithova P, Piskala A, Pitha J, Sorm F, "NUCLEIC ACIDS COMPONENTS AND THEIR ANALOGUES. LXVI.* HYDROLYSIS OF 5-AZACYTIDINE AND ITS CONNECTION WITH BIOLOGICAL ACTIVITY", Collection Czechoslov. Chem. Commun., (19650101), vol. 30, pages 2801 - 2811, XP093131982 | - |
| OPPOSITION | - Raymond C Rowe, Paul J Sheskey, Sian C Owen, "HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Fifth Edition /Passage/", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Fifth Edition, Pharmaceutical Press , (20060101), pages 3pp, 554 - 555, XP055735915 | - |
| OPPOSITION | - Raymond C Rowe, Paul J Sheskey, Sian C Owen, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Fifth Edition, Pharmaceutical Press , (20060101), pages 554 - 555, XP055735915 | - |
| OPPOSITION | - Ritschel Wolfgang, "Die Tablette - Handbuch der Entwicklung, Herstellung und Qualitätssicherung. Auszug", Ritschel Wolfgang, RITSCHEL W.A., Die Tablette Handbuch der Entwicklung, Herstellung und Qualitatssicherung, EDITIO CANTOR VERLAG , (20020101), pages 30 - 30, ISBN 978-3-87193-228-1, XP093039122 | - |
| OPPOSITION | - RITSCHL, WOLFGNG A. et al., Die Tablette - Handbuch der Entwicklung, Herstellung und Quali- tdtssicherung, (20020000), page 30, XP093039122 | - |
| OPPOSITION | - Rowland Malcolm, Tozer Thomas N., Clinical Pharmacokinetics - Concepts and Applications, 3rd. ed, (19950101), pages 11 - 12, 128 - 129, 131 - 132, XP093132017 | - |
| OPPOSITION | - Shargel, Et Al., "Chapter 17: Modified-Release Drug Products", Applied Biopharmaceutics & Pharmacokinetics Fifth Edition, (20050101), page 515, XP055926624 | - |
| OPPOSITION | - Vanderhoff Bruce T., Rundsarah M. Tahboub, "Proton Pump Inhibitors: An Update", AMERICAN FAMILY PHYSICIAN, (20020715), vol. 66, no. 2, pages 273 - 280, XP093132025 | - |
| OPPOSITION | - Carlo Stresemann, Frank Lyko, "Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine", International Journal of Cancer, John Wiley & Sons, Inc., US, US , (20080701), vol. 123, no. 1, doi:10.1002/ijc.23607, ISSN 0020-7136, pages 8 - 13, XP055233070 | |
| OPPOSITION | - Robert E. Notari, Joyce L. Deyoung, "Kinetics and Mechanisms of Degradation of the Antileukemic Agent 5-Azacytidine in Aqueous Solutions", Journal of Pharmaceutical Sciences, (19750701), vol. 64, no. 7, doi:10.1002/jps.2600640704, pages 1148 - 1157, XP055735925 | |
| OPPOSITION | - CHAN et al., "5-Azacytidine Hydrolysis Kinetics Measured by High-pressure Liquid Chromatography and 13C-NMRSpectroscopy", Journal of Pharmaceutical Sciences, (19790000), vol. 68, no. 7, doi:10.1002/jps.2600680705, pages 807 - 812, XP055735923 | |
| OPPOSITION | - Kenneth K. Chan, Donald D. Giannini, J A Staroscik, W Sadee, "5-Azacytidine Hydrolysis Kinetics Measured by High-pressure Liquid Chromatography and 13C-NMR Spectroscopy", Journal of Pharmaceutical Sciences, (19790701), vol. 68, no. 7, doi:10.1002/jps.2600680705, pages 807 - 812, XP055735923 | |
| OPPOSITION | - Chabner, B.A. ; Drake, J.C. ; Johns, D.G., "Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase", Biochemical Pharmacology, Elsevier, US, US , (19731101), vol. 22, no. 21, doi:10.1016/0006-2952(73)90137-8, ISSN 0006-2952, pages 2763 - 2765, XP025886768 | |
| OPPOSITION | - KIDANE A. et al., "Recent advances in small molecule drug delivery", Curr Opin Chem Biol., (20050800), vol. 9, no. 4, doi:10.1016/j.cbpa.2005.06.006, pages 347 - 351, XP004986463 | |
| OPPOSITION | - Kissinger, L.D. ; Stemm, N.L., "Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography", Journal of Chromatography A, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19860226), vol. 353, doi:10.1016/S0021-9673(01)87101-6, ISSN 0021-9673, pages 309 - 318, XP026554325 | |
| OPPOSITION | - HIRAYAMA et al., "Cyclodextrin-based controlled drug release system", Adv. Drug Deliv. Rev., (19990000), vol. 36, no. 1, doi:10.1016/S0169-409X(98)00058-1, pages 125 - 141, XP002616323 | |
| OPPOSITION | - Hirayama F., Uekama K., "Cyclodextrin-based controlled drug release system", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (19990301), vol. 36, no. 1, doi:10.1016/S0169-409X(98)00058-1, ISSN 0169-409X, pages 125 - 141, XP002616323 | |
| OPPOSITION | - GARCIA-MANERO et al., "A pilot pharmacokinetic study of oral azacitidine", Leukemia, (20080612), vol. 22, doi:10.1038/leu.2008.145, pages 1680 - 1684, XP037784418 | |
| OPPOSITION | - G. GARCIA-MANERO et al., "A pilot pharmacokinetic study of oral azacitidine", Leukemia, (20080000), vol. 22, doi:10.1038/leu.2008.145, pages 1680 - 1684, XP055850165 | |
| OPPOSITION | - G Garcia-Manero et al, "A pilot pharmacokinetic study of oral azacitidine", Leukemia, (20080901), vol. 22, no. 9, doi:10.1038/leu.2008.145, ISSN 08876924, pages 1680 - 1684, XP055217511 | |
| OPPOSITION | - G Garcia-Manero, M L Stoltz, M R Ward, H Kantarjian, S Sharma, "A pilot pharmacokinetic study of oral azacitidine", Leukemia, (20080901), vol. 22, no. 9, doi:10.1038/leu.2008.145, ISSN 08876924, pages 1680 - 1684, XP055217511 | |
| OPPOSITION | - G Garcia-Manero, M L Stoltz, M R Ward, H Kantarjian, S Sharma, "A pilot pharmacokinetic study of oral azacitidine", Leukemia, Stockton Press, (20080901), vol. 22, no. 9, doi:10.1038/leu.2008.145, ISSN 08876924, pages 1680 - 1684, XP055217511 | |
| OPPOSITION | - Wei Andrew H., Döhner Hartmut, Pocock Christopher, Montesinos Pau, Afanasyev Boris, Dombret Hervé, Ravandi Farhad, Sayar Hamid, Jang Jun-Ho, Porkka Kimmo, Selleslag Dominik, Sandhu Irwindeep, Turgut Mehmet, Giai Valentina, Ofran Yishai, Kizil Çakar Merih, Botelho De Sousa Aida, Rybka Justyna, Frairia Chiara, Borin Lorenza, Beltrami Germana, Čermák Jaroslav, Ossenkoppele Gert J., La Torre Ignazia, Skikne Barry, Kumar Keshava, Dong Qian, Beach C.L., Roboz Gail J., "Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission", The New England journal of medicine, Massachusetts Medical Society, US, US , (20201224), vol. 383, no. 26, doi:10.1056/NEJMoa2004444, ISSN 0028-4793, pages 2526 - 2537, XP055928137 | |
| OPPOSITION | - "Aspirin", Becker Richard C., Spencer Frederick A., Fibrinolytic and Antithrombotic Therapy: Theory, Practice, and Management , Oxford University Press, (20060427), doi:10.1093/OSO/9780195155648.003.0012, ISBN 978-0-19-756195-9, XP093132019 | |
| OPPOSITION | - Čihák A., Šorm F., "Biochemical effects and metabolic transformations of 5-azacytidine in Escherichia coli", Collection of Czechoslovak chemical communications, (19650101), vol. 30, no. 6, doi:10.1135/cccc19652091, ISSN 0010-0765, pages 2091 - 2102, XP093131355 | |
| OPPOSITION | - Thomson Abr, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B, "Influence of Food on the Bioavailability of an Enteric-Coated Tablet Formulation of Omeprazole 20 mg Under Repeated Dose Conditions", CANADIAN JOURNAL OF GASTROENTEROLOGY., MEDICARE PUBL., OAKVILLE, CA, CA , (19970101), vol. 11, no. 8, doi:10.1155/1997/830856, ISSN 0835-7900, pages 663 - 667, XP093132020 | |
| OPPOSITION | - Amy Ziemba, Eugene Hayes, Burgess B. Freeman, Tao Ye, Giuseppe Pizzorno, "Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine", Chemotherapy Research and Practice, (20110101), vol. 2011, doi:10.1155/2011/965826, ISSN 2090-2107, pages 1 - 9, XP055734492 | |
| OPPOSITION | - Stoltz Maxine L; et al, "Development of an oral dosage form of azacitidine: Overcoming challenges in chemistry, formulation, and bioavailability.", Blood, US , (20060101), vol. 108, no. 11, ISSN 0006-4971, page 298B, XP009121611 | |
| OPPOSITION | - Stoltz Maxine L; Etter Jeffirey B; Obradovic Tanja; Jia Richard, "Development of an oral dosage form of azacitidine: Overcoming challenges in chemistry, formulation, and bioavailability.", Blood, American Society of Hematology, US, US , (20060101), vol. 108, no. 11, ISSN 0006-4971, page 298B, XP009121611 | |
| OPPOSITION | - GARCIA-MANERO et al., "Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes", Blood (ASH Annual Meeting Abstracts, (20120000), vol. 120, no. 124, doi:10.1182/blood.V120.21.424.424, XP055637082 | |
| OPPOSITION | - Guillermo Garcia-Manero, Steven D. Gore, Suman Kambhampati, Bart L Scott, Ayalew Tefferi, Christopher R Cogle, William Edenfield, Joel Hetzer, Keshava Kumar. And Barry S. Skikne, "Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes", Blood (ASH Annual Meeting Abstracts), (20120101), vol. 120, doi:10.1182/blood.V120.21.424.424, XP055637082 | |
| OPPOSITION | - WARD et al., "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", Journal of Clinical Oncology, (20070600), vol. 25, no. 18, page 7084, XP009121612 | |
| OPPOSITION | - Ward M. R., Stoltz M.L., Etter J.B., Patton L.M., Garcia Manero G., Sharma S., "7084 - An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", Journal of Clinical Oncology, (20070620), vol. 25, no. 18_suppl., doi:10.1200/jco.2007.25.18suppl.7084, XP093132028 | |
| OPPOSITION | - GARCIA-MANERO et al., "Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia", J. Clin. Oncol., (20110620), vol. 29, no. 18, doi:10.1200/JCO.2010.34.4226, pages 2521 - 2527, XP055637078 | |
| OPPOSITION | - Guillermo Garcia-Manero, Steven D. Gore, Christopher Cogle, Renee Ward, Tao Shi, Kyle J. Macbeth, Eric Laille, Heidi Giordano, Sarah Sakoian, Elias Jabbour, Hagop Kantarjian, Barry Skikne, "Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia", J. Clin. Oncol., (20110620), vol. 29, no. 18, doi:10.1200/JCO.2010.34.4226, pages 2521 - 2527, XP055637078 | |
| OPPOSITION | - Vaishali A Kilor, Nidhi P. Sapkal, Jasmine G. Awari, And Bharti D. Shewale, "Development and Characterization of Enteric-Coated Immediate-Release PeHcts of Acedofenac by Extrusion/Spheronization Tedmi<Jm..' lJsing K.-Canageenan as a PeUetizing Agent", AAPS PharmSciTech, (20100301), vol. 11, no. 1, doi:10.1208/s12249-010-9389-9, pages 336 - 343, XP055637096 | |
| OPPOSITION | - KAMINSKAS E ET AL, "FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza(TM)) for injectable suspension", THE ONCOLOGIST, (20050301), vol. 10, no. 3 , doi:10.1634/theoncologist.10-3-176, ISSN 1083-7159, pages 176 - 182, XP002803407 | |
| OPPOSITION | - Christopher R Cogle, Bart L. Scott, Thomas Boyd And Guillermo Garcia-Manero, "Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia", The Oncologist, (20150101), vol. 20, doi:10.1634/theoncologist.2015-0165, pages 1 - 9, XP055637090 | |
| OPPOSITION | - COGLE et al., "Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia", The Oncologist, (20150000), vol. 20, doi:10.1634/theoncologist.2015-0165, pages 1 - 9, XP055637090 | |
| OPPOSITION | - Kavita Raj, Mufti Ghulam J, "Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes", THERAPEUTICS AND CLINICAL RISK MANAGEMENT, DOVE MEDICAL PRESS LTD.,, NZ, NZ , (20061201), vol. 2, no. 4, doi:10.2147/tcrm.2006.2.4.377, ISSN 1176-6336, pages 377 - 388, XP055640347 | |
| OPPOSITION | - Kavita Raj, Mufti Ghulam J, "Azacytidine (Vidaza) in the treatment of myelodysplastic syndromes", THERAPEUTICS AND CLINICAL RISK MANAGEMENT, NZ , (20061201), vol. 2, no. 4, doi:10.2147/tcrm.2006.2.4.377, ISSN 1176-6336, pages 377 - 388, XP055640347 | |
| OPPOSITION | - RAJ et al., "Azacytidine in the treatment of myelodysplastic syndromes", Therapeutics and Clinical Risk Management, (20060000), vol. 2, no. 4, doi:10.2147/tcrm.2006.2.4.377, pages 377 - 388, XP055640347 | |
| OPPOSITION | - Paul M. Howell, Liu Zixing, Khong Hung T., "Demethylating Agents in the Treatment of Cancer", Pharmaceuticals, (2010), vol. 3, no. 7, doi:10.3390/ph3072022, pages 2022 - 2044, XP055051867 | |
| OPPOSITION | - Paul M. Howell, Liu Zixing, Khong Hung T., "Demethylating Agents in the Treatment of Cancer", Pharmaceuticals, vol. 3, no. 7, doi:10.3390/ph3072022, pages 2022 - 2044, XP055051867 | |
| SEARCH | - STOLTZ, "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability", ASH ANNUAL MEETING, (20060101), vol. 108, XP009121611 [Y] 1-6 * the whole document * | |
| SEARCH | - WARD, "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", JOURNAL OF CLINICAL ONCOLOGY, (20070701), vol. 25, no. 18S, XP009121612 [Y] 1-6 * the whole document * | |
